Biomarin Pharmaceutical (BMRN) Notes Payables (2010 - 2019)

Biomarin Pharmaceutical (BMRN) has 8 years of Notes Payables data on file, last reported at $6.9 million in Q1 2019.

• Quarterly Notes Payables fell 66.52% year-over-year to $6.9 million in Q1 2019, while the trailing twelve-month figure through Mar 2019 was $6.9 million (down 66.52% YoY) and the FY2018 annual result came in at $4.2 million, down 71.11% from the prior year.
• Notes Payables rose to $6.9 million in Q1 2019, from $4.2 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $20.6 million in Q1 2018 to a low of $4.2 million in Q4 2018.
• A 4-year average of $9.9 million and a median of $7.0 million in 2018 frame the typical range for Notes Payables.
• Annual changes were most pronounced in 2017 — Notes Payables soared 178.1% — and 2018, when it plunged 71.11%.
• Tracing BMRN's Notes Payables over 4 years: stood at $5.2 million in 2016, then surged by 178.1% to $14.5 million in 2017, then sank by 71.11% to $4.2 million in 2018, then jumped by 65.25% to $6.9 million in 2019.
• The last three Notes Payables figures came in at $6.9 million (Q1 2019), $4.2 million (Q4 2018), and $6.4 million (Q3 2018), per Business Quant data.